Literature DB >> 31666279

The Role of the BCL-2 Family of Proteins in HIV-1 Pathogenesis and Persistence.

Aswath P Chandrasekar1, Nathan W Cummins1, Andrew D Badley2,3.   

Abstract

Advances in HIV-1 therapy have transformed the once fatal infection into a manageable, chronic condition, yet the search for a widely applicable approach to cure remains elusive. The ineffectiveness of antiretroviral therapy (ART) in reducing the size of the HIV-1 latent reservoir has prompted investigation into the mechanisms of HIV-1 latency and immune escape. One of the major regulators of apoptosis, the BCL-2 protein, alongside its homologous family members, is a major target of HIV-1-induced change. Recent studies have now demonstrated the association of this protein with cells that support proviral forms in the setting of latency and have helped identify BCL-2 as a novel and promising therapeutic target for HIV-1 therapy directed at possible cure. This review aims to systematically review the interactions of HIV-1 with BCL-2 and its homologs and to examine the possibility of using BCL-2 inhibitors in the study and elimination of the latent reservoir.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  BCL-2 family; antiapoptosis; apoptosis; human immunodeficiency virus

Mesh:

Substances:

Year:  2019        PMID: 31666279      PMCID: PMC6822993          DOI: 10.1128/CMR.00107-19

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  181 in total

1.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.

Authors:  Lin Chen; Simon N Willis; Andrew Wei; Brian J Smith; Jamie I Fletcher; Mark G Hinds; Peter M Colman; Catherine L Day; Jerry M Adams; David C S Huang
Journal:  Mol Cell       Date:  2005-02-04       Impact factor: 17.970

Review 2.  Unravelling the mechanisms of durable control of HIV-1.

Authors:  Bruce D Walker; Xu G Yu
Journal:  Nat Rev Immunol       Date:  2013-07       Impact factor: 53.106

3.  Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis.

Authors:  Peter E Czabotar; Dana Westphal; Grant Dewson; Stephen Ma; Colin Hockings; W Douglas Fairlie; Erinna F Lee; Shenggen Yao; Adeline Y Robin; Brian J Smith; David C S Huang; Ruth M Kluck; Jerry M Adams; Peter M Colman
Journal:  Cell       Date:  2013-01-31       Impact factor: 41.582

4.  HIV Tat protein increases Bcl-2 expression in monocytes which inhibits monocyte apoptosis induced by tumor necrosis factor-alpha-related apoptosis-induced ligand.

Authors:  Lin Zheng; Yida Yang; Lu Guocai; C David Pauza; Maria S Salvato
Journal:  Intervirology       Date:  2007-03-14       Impact factor: 1.763

5.  Autophagy pathway intersects with HIV-1 biosynthesis and regulates viral yields in macrophages.

Authors:  George B Kyei; Christina Dinkins; Alexander S Davis; Esteban Roberts; Sudha B Singh; Chunsheng Dong; Li Wu; Eiki Kominami; Takashi Ueno; Akitsugu Yamamoto; Maurizio Federico; Antonito Panganiban; Isabelle Vergne; Vojo Deretic
Journal:  J Cell Biol       Date:  2009-07-27       Impact factor: 10.539

6.  S-phase entry leads to cell death in circulating T cells from HIV-infected persons.

Authors:  Scott F Sieg; Douglas A Bazdar; Michael M Lederman
Journal:  J Leukoc Biol       Date:  2008-03-27       Impact factor: 4.962

7.  Human immunodeficiency virus induces a dual regulation of Bcl-2, resulting in persistent infection of CD4(+) T- or monocytic cell lines.

Authors:  F Aillet; H Masutani; C Elbim; H Raoul; L Chêne; M T Nugeyre; C Paya; F Barré-Sinoussi; M A Gougerot-Pocidalo; N Israël
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

Review 8.  BH3-only proteins - evolutionarily conserved proapoptotic Bcl-2 family members essential for initiating programmed cell death.

Authors:  Philippe Bouillet; Andreas Strasser
Journal:  J Cell Sci       Date:  2002-04-15       Impact factor: 5.285

9.  Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).

Authors:  J D Leverson; H Zhang; J Chen; S K Tahir; D C Phillips; J Xue; P Nimmer; S Jin; M Smith; Y Xiao; P Kovar; A Tanaka; M Bruncko; G S Sheppard; L Wang; S Gierke; L Kategaya; D J Anderson; C Wong; J Eastham-Anderson; M J C Ludlam; D Sampath; W J Fairbrother; I Wertz; S H Rosenberg; C Tse; S W Elmore; A J Souers
Journal:  Cell Death Dis       Date:  2015-01-15       Impact factor: 8.469

10.  Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection.

Authors:  Joseph A Fraietta; Yvonne M Mueller; Guibin Yang; Alina C Boesteanu; Donald T Gracias; Duc H Do; Jennifer L Hope; Noshin Kathuria; Shannon E McGettigan; Mark G Lewis; Luis D Giavedoni; Jeffrey M Jacobson; Peter D Katsikis
Journal:  PLoS Pathog       Date:  2013-10-10       Impact factor: 6.823

View more
  10 in total

Review 1.  Evolving Strategies to Eliminate the CD4 T Cells HIV Viral Reservoir via CAR T Cell Immunotherapy.

Authors:  Jarrod York; Kavitha Gowrishankar; Kenneth Micklethwaite; Sarah Palmer; Anthony L Cunningham; Najla Nasr
Journal:  Front Immunol       Date:  2022-04-29       Impact factor: 8.786

2.  Selective BCL-XL Antagonists Eliminate Infected Cells from a Primary-Cell Model of HIV Latency but Not from Ex Vivo Reservoirs.

Authors:  Yanqin Ren; Szu Han Huang; Amanda B Macedo; Adam R Ward; Winiffer D Conce Alberto; Thais Klevorn; Louise Leyre; Dennis C Copertino; Talia M Mota; Dora Chan; Ronald Truong; Thomas Rohwetter; Paul Zumbo; Friederike Dündar; Doron Betel; Colin Kovacs; Erika Benko; Alberto Bosque; R Brad Jones
Journal:  J Virol       Date:  2021-07-12       Impact factor: 5.103

3.  The long road to TRAIL therapy: a TRAILshort detour.

Authors:  Aswath P Chandrasekar; Mark Maynes; Andrew D Badley
Journal:  Oncotarget       Date:  2021-03-30

4.  Selective cell death in HIV-1-infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir.

Authors:  Shringar Rao; Cynthia Lungu; Raquel Crespo; Thijs H Steijaert; Alicja Gorska; Robert-Jan Palstra; Henrieke A B Prins; Wilfred van Ijcken; Yvonne M Mueller; Jeroen J A van Kampen; Annelies Verbon; Peter D Katsikis; Charles A B Boucher; Casper Rokx; Rob A Gruters; Tokameh Mahmoudi
Journal:  Nat Commun       Date:  2021-04-30       Impact factor: 14.919

Review 5.  Lnc(ing)RNAs to the "shock and kill" strategy for HIV-1 cure.

Authors:  Saikat Boliar; David G Russell
Journal:  Mol Ther Nucleic Acids       Date:  2021-02-10       Impact factor: 8.886

Review 6.  Potential Utility of Natural Killer Cells for Eliminating Cells Harboring Reactivated Latent HIV-1 Following the Removal of CD8+ T Cell-Mediated Pro-Latency Effect(s).

Authors:  Georges Khoury; Deanna A Kulpa; Matthew S Parsons
Journal:  Viruses       Date:  2021-07-26       Impact factor: 5.048

7.  Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma.

Authors:  Masumeh Sanaei; Fraidoon Kavoosi
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

8.  Bcl-xL Reduces Chinese Giant Salamander Iridovirus-Induced Mitochondrial Apoptosis by Interacting with Bak and Inhibiting the p53 Pathway.

Authors:  Yiqun Li; Yuding Fan; Yong Zhou; Nan Jiang; Mingyang Xue; Yan Meng; Wenzhi Liu; Jingjing Zhang; Ge Lin; Lingbing Zeng
Journal:  Viruses       Date:  2021-11-04       Impact factor: 5.048

Review 9.  Senotherapeutics in Cancer and HIV.

Authors:  Laura Sánchez-Díaz; Asunción Espinosa-Sánchez; José-Ramón Blanco; Amancio Carnero
Journal:  Cells       Date:  2022-04-04       Impact factor: 6.600

10.  CircRNA hsa_circ_0013958 may contribute to the development of ovarian cancer by affecting epithelial-mesenchymal transition and apoptotic signaling pathways.

Authors:  Cheng Pei; Han Wang; Cong Shi; Chuanqi Zhang; Min Wang
Journal:  J Clin Lab Anal       Date:  2020-03-10       Impact factor: 2.352

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.